|Articles|August 10, 2018

West Nile Virus Activity Reported in 40 States and District of Columbia

In addition to over 100 cases across the country, the first case of WNV infection for 2018 was just reported in Contagion®’s home base of New Jersey.

West Nile virus (WNV) was first reported in the United States in 1999 and every summer since then the country has seen an increase in cases.

As of August 7, 2018, WNV activity—which includes infections in humans or animals, birds, and mosquitoes—has been reported in 40 states and the District of Columbia (see map). A total of 106 cases of human infection have been confirmed thus far.

According to the CDC, 8 out of 10 individuals who become infected with WNV do not experience any symptoms; however, 1 in 5 will develop a fever and other symptoms such as headache, aches, joint pain, diarrhea, vomiting and fatigue, which can persist for weeks to months.

Approximately 1 in 150 people who experience WNV infection will experience severe neuroinvasive illness and develop severe symptoms including high fever, neck stiffness, disorientation, and coma, which can lead to encephalitis or meningitis. Severe illnesses are more prevalent in individuals over the age of 60 years and those with certain medical conditions including cancer, diabetes, and kidney disease.

Preliminary data for 2018 indicate that, to date, 62 (58%) of the WNV infection cases in the United States have been classified as neuroinvasive, and 44 (42%) have been classified as non-neuroinvasive diseases.

On August 4, 2018, the first case of WNV infection in New Jersey was reported in Hunterdon County, about 42 miles west of Contagion®’s home base of Cranbury, New Jersey. The New Jersey Department of Public Health reported that 284 mosquito pools in 20 counties have tested positive for WNV. This finding is 48% higher than the number of positive pools at the same point in 2017. There were 8 human cases of WNV reported in New Jersey in 2017.

To stave off infection, the CDC recommends using insect repellents with 1 of the following active ingredients: DEET, picaridin, IR3535, lemon eucalyptus oil, para-menthane-diol, or 2-undercanone. Additional prevention measures include wearing long-sleeved shirts and long pants to avoid bites, and draining any items that hold water inside and outside of homes, such as birdbaths, pools, trash containers, and buckets.


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.